Found: 4
Select item for more details and to access through your institution.
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.
- Published in:
- Cancer Management & Research, 2019, v. 11, p. 10463, doi. 10.2147/CMAR.S208720
- By:
- Publication type:
- Article
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma.
- Published in:
- PLoS Medicine, 2008, v. 5, n. 1, p. e8, doi. 10.1371/journal.pmed.0050008
- By:
- Publication type:
- Article
ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi15, doi. 10.1093/neuonc/noy148.052
- By:
- Publication type:
- Article
ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM).
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi10, doi. 10.1093/neuonc/noy148.033
- By:
- Publication type:
- Article